Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelaye, Alehegn, Haidar, Abdallah, Kassab, Christina, Kazmi, Syed, Sinha, Prabhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819091/
https://www.ncbi.nlm.nih.gov/pubmed/27088018
http://dx.doi.org/10.1155/2016/1656182
_version_ 1782425137614684160
author Gelaye, Alehegn
Haidar, Abdallah
Kassab, Christina
Kazmi, Syed
Sinha, Prabhat
author_facet Gelaye, Alehegn
Haidar, Abdallah
Kassab, Christina
Kazmi, Syed
Sinha, Prabhat
author_sort Gelaye, Alehegn
collection PubMed
description Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.
format Online
Article
Text
id pubmed-4819091
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48190912016-04-17 Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern Gelaye, Alehegn Haidar, Abdallah Kassab, Christina Kazmi, Syed Sinha, Prabhat Case Rep Crit Care Case Report Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition. Hindawi Publishing Corporation 2016 2016-03-21 /pmc/articles/PMC4819091/ /pubmed/27088018 http://dx.doi.org/10.1155/2016/1656182 Text en Copyright © 2016 Alehegn Gelaye et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Gelaye, Alehegn
Haidar, Abdallah
Kassab, Christina
Kazmi, Syed
Sinha, Prabhat
Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_full Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_fullStr Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_full_unstemmed Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_short Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_sort severe ketoacidosis associated with canagliflozin (invokana): a safety concern
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819091/
https://www.ncbi.nlm.nih.gov/pubmed/27088018
http://dx.doi.org/10.1155/2016/1656182
work_keys_str_mv AT gelayealehegn severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT haidarabdallah severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT kassabchristina severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT kazmisyed severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT sinhaprabhat severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern

Ejemplares similares